Audit: QRS - Spirulina, Chlorella, MCP & Modified Alginate Complex for Heavy Metal Detoxification

Audit conducted on 05/08/2026 22:00 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (4.5 g/day 2:1 MCP-alginate, 6–10 g/day chlorella, 1–8 g/day spirulina, 15–20 g/day powder, 30–60 min before meals, bedtime dose), all 18 benefit items, all 17 risk items, all 8 contraindications, all 15 interactions, all 11 biomarker rows and the cadence line trace to ER lines 198–310, 336–439, 459–489, 515–527, 572, 594–619.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s cautious framing is carried by tier placement: “increased urinary excretion of toxic elements” and “reduced body burden of multiple metals” sit in Low, the uranium/methylmercury/galectin-3 items in Speculative, mirroring ER lines 272–309.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication strength preserved: “Phenylketonuria (absolute)” stays absolute; pregnancy/breastfeeding remains conditional on batch certification, matching ER line 489. No caution item is upgraded to a contraindication or vice versa.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Every gate item derives from ER Key Interactions & Contraindications (lines 459–489); every risk item from Potential Risks & Side Effects (lines 336–439). No content from Benefit-Modifying Factors (312–326) or Risk-Modifying Factors (442–454) appears in the gates or risk card.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no NCT identifiers, no expert names and no brand names (PectaSol, PectaClear, EcoNugenics all absent); study references are generic (“the arsenic trial”, “the pediatric lead study”, “the case series”).
1.6	The QRS does not introduce new attributions.	🟢	No named sources, authors, institutions or organisations appear anywhere in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The QRS reproduces the ER’s sceptical-but-practical register: binding chemistry accepted, human evidence described as thin, contamination named as the central paradox — matching ER lines 647–651.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and doses throughout, with the At-A-Glance closing on the actionable lever (“product choice and dose timing can remove most of the hazard”).
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as observed protocol parameters and measured targets, not as instructions issued to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical directives; the footer disclaimer states the sheet is not medical advice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommended”, “advised”, “should” or “we suggest” anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Grep of the rendered body returns zero occurrences of “you” or “your”.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Terms are spelled out rather than abbreviated (“thyroid stimulating hormone”, “alanine aminotransferase”, “estimated glomerular filtration rate”), following the ER’s own no-acronym convention.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lists are semicolon-joined noun phrases; monitoring “why” cells run ~50 characters; drug example lists are trimmed to two representatives each.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by the same check as 2.6 — no second-person address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes willingness to run an 11-marker baseline panel, unprovoked speciated testing and a certificate-of-analysis-gated product choice.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing 2–3 times daily on an empty stomach, four-hour medication separation and a repeat panel every 6 months are presented without hedging on inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional biomarker targets tighter than conventional reference ranges (whole blood lead < 1 µg/dL, ferritin 50–150 ng/mL) are aimed at an optimizing audience, not the general population.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance foregrounds the contamination paradox and the seller-funded evidence base — the two considerations that matter most to a risk-aware self-experimenter.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Zero occurrences of “anti-aging” in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terms used throughout (“gastrointestinal symptoms”, “anaphylaxis”, “narrow-therapeutic-index oral medications”, “esophageal stricture”); no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Heading extraction from the QRS returns exactly the same set as the template: Protocol, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, plus the “Time to effect” subhead, both gate headings, all four tier labels and Marker/Target/Why.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template span names are present; the four repeatable template patterns (marker_#name / _target / _why and qualitative_item#) are expanded to 11 marker rows and 6 qualitative items, giving 73 spans with no template span missing.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template shows only variable-content differences; the non-variable spans website="evidence_review", website="audit" and website="full_review" are byte-identical to the template, as are the stylesheet, CSS block and footer disclaimer.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty; every benefit tier, risk tier, gate and monitoring row has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels are the ER’s own bold bullet labels verbatim: “Modified citrus pectin dosing” (ER 517), “Chlorella dosing” (ER 519), “Timing and time of day” (ER 525).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names reproduce the ER biomarker column in full without abbreviation (“Estimated glomerular filtration rate with cystatin C”, “Alanine aminotransferase with gamma-glutamyl transferase”).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; the ER’s ⚠️ Conflicted markers and tier emoji are correctly dropped, with tiering carried by the bold High/Medium/Low/Speculative labels and the CSS palette.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the floor permitted by the mandatory completeness items (8.2, 9.2, 12.1, 13.1, 14.2, 15.2): tier lists collapsed to semicolon-joined noun phrases, interaction drug examples trimmed from four to two, monitoring rationales cut to ~50 characters and the cadence compressed to a single line. No section is carried at ER length.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14 hold a single HTML comment immediately after <!doctype html> on line 1, preceding the template comment on line 16 and <html> on line 17.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Line 3 opens with --- and line 13 closes with ---; the descriptive text on line 2 precedes the opening delimiter as permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block is inside an HTML comment and no metadata value is echoed anywhere in <head> or <body>.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine values are trimmed; only duration: "00:05" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: spirulina_chlorella_mcp_modified_alginate_complex_detoxification_2026-0805-1658_Opus_ER.md, matching the ER’s own filename frontmatter field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0805-2110, correctly formatted.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 states qrs_filename: spirulina_chlorella_mcp_modified_alginate_complex_detoxification_2026-0805-1658_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; git_user: evipedia-2 and git_issue: 4813 are correctly unquoted, duration: "00:05" correctly quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Spirulina, Chlorella, MCP & Modified Alginate Complex for Heavy Metal Detoxification - Quick Reference Sheet”, with the ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417 matches the ER canonical_topic (ER line 8) exactly, with & encoding.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/05/2026”, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0805-2110.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the qrs_creator_ai_fullname frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template’s fixed subline; the ER’s long “Also known as” list (ER line 30) is not reproduced.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 647–651: the binding chemistry, the thin and conflicted human evidence, the contamination paradox, and the actionable lever of product choice and dose timing.
7.2	[at_a_glance] is no longer than 60 words	🟢	Programmatic word count returns 59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“binding chemistry is real” ← ER 647; “small studies without comparison groups, most funded by the seller” ← ER 649; “Testing keeps finding lead in these products” ← ER 651; “product choice and dose timing can remove most of the hazard” ← ER 651.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “two algae and two plant fibers”, “stored metal”, “the seller” rather than MCP, rhamnogalacturonan-II, enterohepatic recirculation or body burden.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, author, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No percentages, confidence intervals or standardized mean differences appear; the ER’s 74 percent and 130/150 percent figures are correctly excluded.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to the “Populations who should avoid this intervention” bullet at ER line 489.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER-listed populations are present: phenylketonuria, active autoimmune disease, transplant recipients, pregnancy/breastfeeding without certification, chronic kidney disease stage 4+, algae/seaweed/mold/citrus allergy, dysphagia or esophageal stricture, and elevated uric acid or gout.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements inside the stop_items span (lines 562–569).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No em-dash or en-dash appears in the gate; the ER’s explanatory glosses (“an autoimmune condition in which the immune system drives the thyroid to overproduce hormone”, “the calculated measure of kidney filtering capacity”, “given placental and milk transfer”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserved: “(absolute)” for phenylketonuria, “(algae components)” on both immunological items, “stage 4 or worse (filtration rate below 30 mL/min/1.73 m²)”, “above 7 mg/dL”, “(gel-forming powders)”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullet uses no ranking notation inside parentheses; thresholds are written out in words (“below 30 mL/min/1.73 m²”, “above roughly 7 mg/dL”).
8.7	If no [stop_items] are present the section is left empty	N/A	Eight contraindications are present, so the condition does not apply.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All fifteen items map one-to-one onto the fifteen interaction bullets at ER lines 459–487.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All fifteen ER interaction bullets are represented and none duplicates a contraindication; the immunosuppressant entry remains a caution while only the transplant-recipient subset appears as a contraindication, matching the ER’s “caution to absolute contraindication depending on indication” (ER 467).
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Fifteen discrete <li> elements inside the caution_items span (lines 577–591).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No em-dash or en-dash appears; every ER “Caution/Monitor — consequence — Mitigation” clause is stripped, leaving only the drug or supplement class.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists are retained but trimmed to two representatives each, as permitted: “(warfarin, phenprocoumon)”, “(doxycycline, ciprofloxacin)”, “(tacrolimus, methotrexate)”, “(calcium carbonate, omeprazole)”, “(theophylline, acetaminophen)”, “(amiodarone, kelp)”. None is dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets contain no ranking notation inside parentheses; all parenthetical content is plain comma-separated drug lists.
9.7	If no [caution_items] are present the section is left empty	N/A	Fifteen key interactions are present, so the condition does not apply.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 515–527.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Fiber-binder dose, algae dose and administration timing are the three parameters a user must set; the ER’s competing-approaches, genetics, sex and age bullets are contextual rather than actionable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects, so all three sets are used and the condition does not apply.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans are populated: 4.5 g/day at a 2:1 ratio with 15–20 g/day powder noted (ER 515, 517); 6–10 g/day chlorella with spirulina 1–8 g/day and broken-cell-wall form (ER 519, 521); empty stomach, 2–3 divided doses, 30–60 minutes before meals or 2 hours after with a bedtime dose (ER 525, 527).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Symptomatic change, body burden and metal output are exactly the three horizons the ER enumerates at line 572.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Symptomatic change maps to the Medium-tier arsenic skin-lesion benefit (ER 209), while body burden and metal output map to Low-tier benefits (ER 272, 278), so the Medium-tier item leads.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect horizons, so all three sets are used and the condition does not apply.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans are populated: 16 weeks for skin lesion improvement, weeks to months for falling blood or hair levels with the 2–4 week pediatric study and 7-month case series, and 1–6 days for urinary or fecal output (ER 572).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides an explicit “Time to effect” bullet at line 572, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eighteen ER benefit headings (lines 198–309) are represented, with tier assignment matching the ER exactly: 1 High, 8 Medium, 6 Low, 3 Speculative.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated (lines 526–552).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is a bare noun phrase; the ER’s Magnitude lines (10–47 mg/dL cholesterol, 47.1 percent hair arsenic, standardized mean differences of 0.49 and 0.72) are all excluded.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit tier; the ER’s glosses (“a unitless measure of effect size”, “a weighted sum expressing a mixture…”) and the ⚠️ Conflicted markers are stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER, so no span needs hiding and the condition does not apply.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seventeen ER risk headings (lines 336–439) are represented, with tier assignment matching the ER exactly: 2 High, 4 Medium, 8 Low, 3 Speculative.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated (lines 603–630).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Study qualifiers are stripped: “Liver Injury and Muscle Breakdown in Isolated Case Reports” → “liver injury and muscle breakdown”; “Mineral Depletion with Long-Term High-Dose Binder Use” → “mineral depletion”.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk tier; the ER’s glosses (“beta-methylamino-L-alanine, a compound investigated as…”, “raised itchy welts, commonly called hives”) are all removed.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER, so no span needs hiding and the condition does not apply.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER biomarker table at lines 598–610 and the cadence paragraph at lines 594–596.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eleven ER biomarkers are present with their optimal functional ranges intact: blood lead, blood/urine cadmium, speciated mercury, speciated urine arsenic, ferritin with transferrin saturation, zinc and selenium, estimated glomerular filtration rate with cystatin C, urine beta-2 microglobulin, thyroid stimulating hormone with free thyroxine, alanine aminotransferase with gamma-glutamyl transferase, and serum uric acid.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 771 carries the full cadence: baseline before the first dose with unprovoked specimens only, metal panel and kidney function at 8–12 weeks with thyroid stimulating hormone where alginate is used, full panel every 6 months, and a final panel 3 months after stopping — matching ER lines 594 and 596.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the qualitative marker list at ER lines 614–619.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six are present: energy and exercise tolerance on a weekly 1–10 scale, cognitive clarity and recall, sleep quality and latency, stool frequency and form, sun-exposed skin appearance, and headache, metallic taste or malaise after a dose increase.

Issues 05/08/2026 22:00

Pass rate 100.00%. No issues found.

Issues 05/08/2026 21:50

1. 4.5 — Sheet overflows one A4 page: Rendered content runs to roughly two A4 pages; the Key Interactions gate (lines 592–608) carries three to five example drugs per item and the Monitoring “Why” column (lines 662–782) averages two to three rendered lines per row, with further slack in the protocol sub-cells, the cadence line and the qualitative items.

Fixes 05/08/2026 21:50

1. 4.5 — Key Interactions gate condensed: Trimmed the example drug list of each caution item to at most two representative agents and shortened the class labels (e.g., “Other supplements with additive metal-binding or laxative effect (activated charcoal, bentonite clay, cholestyramine, psyllium, dimercaptosuccinic acid)” → “Other metal-binding or laxative supplements (activated charcoal, cholestyramine)”), cutting the gate by roughly a third without dropping any of the 15 interactions.
2. 4.5 — Monitoring “Why” column shortened: Rewrote all 11 marker_#_why cells to single-line statements (e.g., marker_10_why from “Detects liver injury from microcystin contamination and tracks the organ that handles biliary metal excretion” to “Detects microcystin liver injury; tracks biliary excretion”), removing about ten rendered lines from the table.
3. 4.5 — Monitoring cadence tightened: Compressed monitoring_cadence from 255 to 222 characters by merging the 8–12 week metal, kidney and thyroid rechecks into one clause while keeping the unprovoked-baseline, 6-monthly and post-stop panels intact.
4. 4.5 — Contraindications trimmed: Shortened the two longest stop_items — “estimated glomerular filtration rate below 30 mL/min/1.73 m²” to “filtration rate below 30 mL/min/1.73 m²” and “above roughly 7 mg/dL … limit total algae intake” to “above 7 mg/dL … limit algae intake” — with both thresholds preserved.
5. 4.5 — Protocol subs and qualitative items condensed: Removed the explanatory tails from the three action sub-cells and the six qualitative items (e.g., “Stool frequency, form and comfort, the earliest signal that the dose was escalated too quickly” → “Stool frequency, form and comfort”), bringing each to a single rendered line.

Issues 05/08/2026 21:39

1. 4.5 — Content overruns one A4 page: The Key Interactions gate carries 15 items with full parenthetical drug lists (lines 594–608) and the Benefits and Risks tier lines run to four rendered lines each (lines 546–552, 634–640), pushing the estimated rendered height to roughly twice the A4 budget.
2. 12.3 — Benefit items carry qualifiers: Benefit entries retain trailing qualifiers, study details and mechanistic elaboration that the tier already encodes, e.g. “in chronic arsenic exposure” (line 547), “in overweight adults” (line 552), “with the pectin-alginate combination” (line 559) and “as a downstream anti-fibrotic effect” (line 567).
3. 13.3 — Risk items carry study details: Risk entries retain study details and mechanism, e.g. “in isolated case reports” (line 639), “with long-term high-dose binder use” (line 644) and “from antiplatelet activity” (line 645).

Fixes 05/08/2026 21:39

1. 4.5 — Key Interactions gate condensed: Trimmed the parenthetical example-drug lists in all 15 caution items to the leading representatives (e.g. warfarin/acenocoumarol/phenprocoumon → warfarin, phenprocoumon; the eight-item binder list → activated charcoal, bentonite clay, cholestyramine, psyllium, dimercaptosuccinic acid), and dropped the redundant “levothyroxine” repetition from the narrow-therapeutic-index item, cutting roughly a third of the gate’s rendered height without dropping any interaction class.
2. 4.5 — Qualitative Assessment and cadence condensed: Stripped the trailing explanatory clauses from all six qualitative items (e.g. “…rather than from memory”, “…and most susceptible to expectation”) and compressed the monitoring cadence sentence, removing a further six rendered lines.
3. 12.3 — Benefit qualifiers stripped: Removed “from the alginate component” from the reflux benefit, “with the pectin-alginate combination” from the body-burden benefit, and “as a downstream anti-fibrotic effect” from the galectin-3 entry. Population-scope qualifiers (“in chronic arsenic exposure”, “in overweight adults”, “in fatty liver disease”, “in humans”) were deliberately retained, since removing them would broaden the ER’s claims and breach item 1.3.
4. 13.3 — Risk study details stripped: Removed “in isolated case reports” from the liver injury entry, “with long-term high-dose binder use” from mineral depletion, and “from antiplatelet activity” from increased bleeding tendency, leaving the bare key fact in each case.

Issues 05/08/2026 21:33

1. 4.2 / 4.3 — Protocol cell labels invented: action_1_label “Fiber binder” (QRS line 449) and action_2_label “Algae, added separately” (QRS line 463) are invented labels rather than the ER’s own bold bullet labels “Modified citrus pectin dosing:” (ER line 517) and “Chlorella dosing:” (ER line 519); only action_3_label “Timing and time of day” is taken verbatim.

Fixes 05/08/2026 21:33

1. 4.2 / 4.3 — Protocol cell labels taken from the ER: action_1_label changed from the invented “Fiber binder” to the ER bold label “Modified citrus pectin dosing” and action_2_label from “Algae, added separately” to “Chlorella dosing”; action_2_value was reduced to “6–10 g/day” and the “added separately” qualifier moved into action_2_sub, and the now-redundant opening of action_1_sub was shortened to “2:1 ratio with sodium alginate”.

Issues 05/08/2026 21:25

1. 4.2 / 4.3 — Protocol timing label abbreviated: action_3_label at line 477 reads “Timing”, an abbreviation of the ER bullet label “Timing and time of day” (ER line 525), so the ER’s bold label is not carried through verbatim.
2. 4.2 / 4.3 — Narrow-therapeutic-index label reformulated: The eighth caution item at line 601 reads “Narrow-therapeutic-index oral medications (digoxin, lithium, phenytoin, levothyroxine)”, a reordering of the ER’s bold label “Digoxin, lithium, phenytoin, levothyroxine and other narrow-therapeutic-index oral medications” (ER line 473).

Fixes 05/08/2026 21:25

1. 4.2 / 4.3 — Protocol timing label restored: action_3_label changed from “Timing” to the ER’s verbatim bullet label “Timing and time of day”.
2. 4.2 / 4.3 — Narrow-therapeutic-index label restored: The eighth caution item changed from “Narrow-therapeutic-index oral medications (digoxin, lithium, phenytoin, levothyroxine)” to the ER’s verbatim label “Digoxin, lithium, phenytoin, levothyroxine and other narrow-therapeutic-index oral medications”.

Issues 05/08/2026 21:18

1. 1.3 — At-a-glance overstates mitigation: [at_a_glance] (line 437) asserts “product choice and dose timing remove most of the hazard”, while the ER Conclusion (line 651) frames it as a capability — “careful product selection and dose timing can largely remove”.
2. 4.3 — Analgesic label qualifier dropped: [caution_items] line 599 shortens the ER label “Over-the-counter analgesics and antiplatelet agents” (ER line 469) to “Analgesics and antiplatelet agents”, broadening the interaction beyond the over-the-counter class the ER scopes it to.

Fixes 05/08/2026 21:18

1. 1.3 — At-a-glance mitigation claim softened: Changed [at_a_glance] from “product choice and dose timing remove most of the hazard” to “product choice and dose timing can remove most of the hazard”, restoring the ER Conclusion’s capability framing; the section remains within the 60-word budget at 59 words.
2. 4.3 — Analgesic label qualifier restored: Changed the [caution_items] entry from “Analgesics and antiplatelet agents” back to the ER’s verbatim label “Over-the-counter analgesics and antiplatelet agents”, with the drug list unchanged.